WEE1

Wee1-like protein kinase

48,725 patent compounds predicted against WEE1, 32,356 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL214495	0.53	17/20
SCHEMBL216617	0.53	17/20
SCHEMBL215881	0.54	16/20
SCHEMBL215852	0.56	15/20
SCHEMBL216546	0.55	15/20
SCHEMBL189352	0.52	15/20
SCHEMBL214278	0.51	15/20
SCHEMBL219529	0.56	14/20
SCHEMBL217692	0.51	14/20
Hydrochloric Acid (SCHEMBL218585)	0.51	14/20
SCHEMBL214363	0.50	14/20
SCHEMBL217029	0.58	13/20
SCHEMBL215998	0.55	12/20
SCHEMBL214554	0.53	12/20
SCHEMBL1115541	0.52	9/20
SCHEMBL1115328	0.52	8/20
SCHEMBL868129	0.75	5/20
SCHEMBL374566	0.52	5/20
SCHEMBL1116423	0.51	5/20
SCHEMBL1115542	0.48	5/20

Germline variants in WEE1 on Sugi Variant → ClinVar classifications, population frequency, and predictor agreement (AlphaMissense, SaProt, REVEL) Full WEE1 gene report on Sugi Atlas → Gene function, pathways, protein structure, constraint & interactions

Clinical trials — most relevant to WEE1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression	PHASE3	RECRUITING
Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING
Study With Wee-1 Inhibitor AZD1775 (MK-1775) and Carboplatin to Treat p53 Mutated Refractory and Resistant Ovarian Cancer	PHASE2	COMPLETED
Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer	PHASE2	ACTIVE_NOT_RECRUITING
Dose Escalation Trial of AZD1775 and Gemcitabine (+Radiation) for Unresectable Adenocarcinoma of the Pancreas	PHASE1/PHASE2	COMPLETED
AZD1775 in Women With Recurrent or Persistent Uterine Serous Carcinoma or Uterine Carcinosarcoma	PHASE2	ACTIVE_NOT_RECRUITING
SC0191 Plus Chemotherapy in Advanced Ovarian Canceradvanced Ovarian Cancer	PHASE1/PHASE2	UNKNOWN
Phase II, Single-arm Study of AZD1775 Monotherapy in Relapsed Small Cell Lung Cancer Patients	PHASE2	COMPLETED
AZD1775 in Treating Patients With Advanced Refractory Solid Tumors With CCNE1 Amplification	PHASE2	COMPLETED
A Study of LY2606368 (Prexasertib) in Patients With Solid Tumors With Replicative Stress or Homologous Repair Deficiency	PHASE2	COMPLETED
To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.	PHASE2	ACTIVE_NOT_RECRUITING
Lomustine Combined With Anlotinib as Interventional Therapy for Extensive-stage Small Cell Lung Cancer Resistant to Second-line and Above Treatment	PHASE2	NOT_YET_RECRUITING
AZD1775 for Advanced Solid Tumors	PHASE1	COMPLETED
AZD1775 Continued Access Study to Assess Safety and Tolerability for Patients Enrolled in AZD1775 Clinical Pharmacology Studies	PHASE1	COMPLETED
Wee1 Kinase Inhibitor AZD1775 and Combination Chemotherapy in Treating Children, Adolescents and Young Adults With Relapsed or Refractory Acute Myeloid Leukemia	PHASE1	WITHDRAWN
Study of SGR-3515 In Participants With Advanced Solid Tumors.	PHASE1	RECRUITING
A Phase I Study of SY-4835 in Patients With Advanced Solid Tumors	PHASE1	UNKNOWN
Study of ISM6331 in Participants With Advanced/Metastatic Malignant Mesothelioma or Other Solid Tumors	PHASE1	RECRUITING
Phase I Study to Assess the Safety, Pharmacokinetics, & Pharmacodynamics of GSK923295 in Subjects w/ Refractory Cancer	PHASE1	COMPLETED
A Phase l Study of By101298, an Oral DNA-PK Inhibitor, in Patients With Advanced Solid Tumors	PHASE1	ACTIVE_NOT_RECRUITING
Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial	PHASE1	RECRUITING
A Study to Assess Safety and Efficacy of SOT201 in Patients With Advanced/Metastatic Cancer	PHASE1	RECRUITING
ZN-c3 for the Treatment of Metastatic Triple-Negative Breast Cancer and Advanced Ovarian Cancer	EARLY_PHASE1	WITHDRAWN
Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212	EARLY_PHASE1	COMPLETED
The Screening Protocol for The VIKTORY Trial	nan	COMPLETED
Biomarkers in Blood and Tissue Samples From Patients With Epstein-Barr Virus-Positive Hodgkin Lymphoma	nan	COMPLETED
Study of the Effect of Innate on the Inflammatory Response to Endotoxin	nan	RECRUITING
Resistance to the Tyrosine Kinase Inhibitor Osimertinib and Pharmacokinetics in Non-small Cell Lung Cancer	nan	ACTIVE_NOT_RECRUITING
Thymidine Kinase 1 in Risk Assessment for Hereditary Breast /Ovarian Cancer	nan	UNKNOWN
Aberrant Splicings Due to Microsatellite Instability in Colorectal Cancer : Physiopathological and Clinical Impact	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a WEE1 binder may also engage these)

Protein	Name	Similarity
Q63802	—	1.000	Q63802 →
P47810	—	1.000	P47810 →
Q8AYK6	—	0.993	Q8AYK6 →
Q8QGV2	—	0.989	Q8QGV2 →
A4QNA8	—	0.976	A4QNA8 →
Q9WU40	—	0.976	Q9WU40 →
Q4R4I0	—	0.975	Q4R4I0 →
TERF2IP	Telomeric repeat-binding factor 2-interacting protein 1	0.974	landscape →
Q6ZWB6	—	0.973	Q6ZWB6 →
Q62925	—	0.973	Q62925 →
Q6DFE0	—	0.973	Q6DFE0 →
Q50H33	—	0.972	Q50H33 →
D2HHP1	—	0.972	D2HHP1 →
Q99MU3	—	0.972	Q99MU3 →
P53349	—	0.972	P53349 →
Q9Y2U8	—	0.971	Q9Y2U8 →
P34908	—	0.971	P34908 →
P12755	—	0.971	P12755 →
Q5SUE8	—	0.971	Q5SUE8 →
Q80Z30	—	0.971	Q80Z30 →
Q8K4J0	—	0.971	Q8K4J0 →
P0C6S7	—	0.971	P0C6S7 →
Q496Y0	—	0.971	Q496Y0 →
A4FV61	—	0.970	A4FV61 →
BCR	Breakpoint cluster region protein	0.970	landscape →
STK35	Serine/threonine-protein kinase 35	0.970	landscape →
Q8K2W6	—	0.970	Q8K2W6 →
Q5QP82	—	0.970	Q5QP82 →
Q8WY91	—	0.970	Q8WY91 →
P49797	—	0.970	P49797 →